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ABSTRACT 
Analysis of sleep for the diagnosis of sleep disorders such as Type-1 Narcolepsy (T1N) currently 
requires visual inspection of polysomnography records by trained scoring technicians. Here, we used 
neural networks in approximately 3,000 normal and abnormal sleep recordings to automate sleep 
stage scoring, producing a hypnodensity graph—a probability distribution conveying more 
information than classical hypnograms. Accuracy of sleep stage scoring was validated in 70 subjects 
assessed by six scorers. The best model performed better than any individual scorer (87% versus 
consensus). It also reliably scores sleep down to 5 instead of 30 second scoring-epochs. A T1N 
marker based on unusual sleep-stage overlaps achieved a specificity of 96% and a sensitivity of 
91%, validated in independent datasets. Addition of HLA-DQB1*06:02 typing increased specificity to 
99%. Our method can reduce time spent in sleep clinics and automates T1N diagnosis. It also opens 
the possibility of diagnosing T1N using home sleep studies.  
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INTRODUCTION 
Sleep disorders and sleep dysregulation impact over 100 million Americans, contributing to medical 
consequences such as cardiovascular (arrhythmia, hypertension, stroke), metabolic (diabetes, 
obesity) and psychiatric disorders (depression, irritability, addictive behaviors). Sleep deprivation 
impairs performance, judgment, mood, and is a major preventable contributor to accidents1. There 
are ~90 different sleep disorders including insomnia (20% of population), obstructive and central 
sleep apnea (10%), restless legs syndrome (4%), Rapid Eye Movement (REM) sleep behavior 
disorder (RBD) and hypersomnia syndromes such as type 1 narcolepsy (T1N)2.  
Among these pathologies, T1N is unique as a disorder with a known, discrete pathophysiology—a 
destruction of hypocretin neurons in the hypothalamus likely of autoimmune origin3. This is reflected 
in the cerebrospinal fluid (CSF) concentrations of the hypocretin-1 (orexin-A) neuropeptide, where a 
concentration below 110 pg/ml is considered indicative of narcolepsy2. Typically beginning in 
childhood or adolescence, narcolepsy affects approximately 0.03% of the US, European, Korean 
and Chinese populations4. Unique to narcolepsy is the extremely strong (97% versus 25%) 
association with a genetic marker, HLA-DQB1*06:025, and a well characterized set of sleep 
disturbances that include short sleep latency, rapid transitions into REM sleep and poor nocturnal 
sleep consolidation. The pathology also includes episodes of "sleep/wake dissociation" where the 
patient is half awake and half in REM sleep, for example experiencing REM sleep muscle paralysis 
while awake (sleep paralysis, cataplexy) or dreaming while awake (hypnagogic hallucinations).  
Sleep disorders are generally assessed at sleep clinics by performing sleep analysis using nocturnal 
polysomnography (PSG), a recording comprised of multiple digital signals which include 
electroencephalography (EEG), electrooculography (EOG), chin and leg electromyography (EMG), 
electrocardiography (ECG), breathing effort, oxygen saturation, and airflow6. When sleep is analyzed 
in PSGs, it is divided into discrete stages: wake, non REM (NREM) sleep stage 1 (N1), 2 (N2) and 
3 (N3), and REM. Each stage is characterized by different criteria, as defined by consensus rules 
published in the American Academy of Sleep Medicine (AASM) Scoring Manual6,7. N1 (sleep onset) 
is characterized by slowing of the EEG, disappearance of occipital alpha waves, decreased EMG 
and slow rolling eye movements, while N2 is associated with spindles and K-complexes. N3 is 
characterized by a dominance of slow, high amplitude waves (>20%), while REM sleep is associated 
with low voltage, desynchronized EEG with occasional saw tooth waves, low muscle tone and REMs. 
PSG analysis is typically done by certified technicians who, through visual inspection on a 
standardized screen, assign a sleep stage to each 30 second segment of the full recording. Although 
there is progression from N1 to N3 then to REM during the night, a process that repeats 
approximately every 90 minutes (the sleep cycle), each stage is associated with physiological 
changes that can be meaningful to the assessment of sleep disorders such as obstructive sleep 
apnea. For example, the abnormal breathing events that occur with Obstructive Sleep Apnea (OSA) 
are generally less severe in N3 versus N2 because central control of breathing changes, and they 
are more severe in REM sleep, due to upper airway muscle weakness8. The differentiation of sleep 
stages is also particularly important for the diagnosis of narcolepsy, a condition currently assessed 
by a PSG followed by a Multiple Sleep Latency Test (MSLT), a test where patients are asked to nap 
4-5 times for 20 minutes every 2 hours during the daytime and sleep latency and the presence of 
REM sleep is noted9. A mean sleep latency (MSL) less than 8 minutes (indicative of sleepiness) and 
the presence of at least 2 sleep onset REM periods (SOREMPs, REM latency ≤15 minutes following 
sleep onset in naps) during the MSLT or 1 SOREM plus a REM latency ≤15 minutes during nocturnal 
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PSG is diagnostic for narcolepsy. In a recent large study of the MSLT10, specificity and sensitivity for 
type 1 narcoleptics were, respectively, 98.6% and 92.9% in comparing 516 T1N versus 516 controls 
and 71.2% and 93.4% in comparing 122 T1N cases versus 132 other hypersomnia cases (high 
pretest probability cohort). Similar sensitivity (75-90%) and specificity (90-98%) have been reported 
by others in large samples of hypersomnia cases versus T1N11–15. 
Manual inspection of sleep recordings has many problems. It is time consuming, expensive, 
inconsistent, subjective, and must generally be done offline. In one study, Rosenberg et al.16  found 
inter-scorer reliability for sleep stage scoring to be 82.6% on average, a result consistently found by 
others17–20. N1 and N3 in particular have agreements as low as 63% and 67%, placing constraints 
on their usefulness16. In this study, we explored whether deep learning, a specific subtype of machine 
learning, could produce a fast, inexpensive, objective, and reproducible alternative to manual sleep 
stage scoring. In recent years, similar complex problems such as labeling images, understanding 
speech and translating language have seen advancement to the point of outperforming humans21–
23. In recent years, several high-profile papers have also documented the efficacy of deep learning 
algorithms in the healthcare sector, especially in the fields of diabetic retinopathy24,25, digital 
pathology26,27, and radiology28,29. This technology refers to complex neural network models with a 
very large number (on a magnitude of millions) of parameters and processing layers. For a thorough 
review of the underlying theory behind deep learning including common model paradigms, we refer 
to the review article by LeCun, Bengio and Hinton (2015)30.  
In this implementation of deep learning, we introduce the hypnodensity graph – a hypnogram that 
does not enforce a single sleep stage label, but rather a membership function to each of the sleep 
stages, allowing more information about sleep trends to be conveyed, something that is only possible 
in non-human scoring. Using this concept, we next applied deep learning-derived hypnodensity 
features to the diagnosis of T1N, showing that an analysis of a single PSG night can perform as well 
as the PSG-MSLT gold standard, a 24-hour long procedure. 
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RESULTS 
 
Inter-scorer reliability cohort 
Supplementary Table 1 reports on the description of the various cohorts included in this study, and 
how they were utilized (see datasets section in Methods). These originate from seven different 
countries. We assessed inter-scorer reliability using the Inter-scorer Reliability Cohort (IS-RC)31, a 
cohort of 70 PSGs scored by 6 scorers across three locations in the Unites States31. Table 1 displays 
individual scorer performance as well as the averaged performance across scorers, with top and 
bottom of table showing accuracies and Cohen’s kappa’s, respectively. The results are shown for 
each individual scorer when compared to the consensus of all scorers (biased) and compared to the 
consensus of the remaining scorers (unbiased). In the event of no majority vote for an epoch, the 
epoch was counted equally in all classes in which there was disagreement.  Also shown in Table 1 
is the model performance on the same consensus scorings as each individual scorer along with the 
t-statistic and associated p-value for each paired t-test between the model performance and 
individual scorer performance. At a significance level of 5%, the model performs statistically better 
than any individual scorer both in terms of accuracy and Cohen’s kappa. 
 
Supplementary Table 2 displays the confusion matrix for every epoch of every scorer of the inter-
scorer reliability data, both un-adjusted (top) and adjusted (bottom). As in Rosenberg et al.16, the 
biggest discrepancies occur between N1 and Wake, N1 and N2, and N2 and N3, with some errors 
also occurring between N1 and REM, and N2 and REM.  
 
For future analyses of the IS-RC in combination with other cohorts that have been scored only by 
one scorer, a final hypnogram consensus was built for this cohort based on the majority vote 
weighted by the degree of consensus from each voter, expressed as its Cohen’s 𝜅𝜅, 𝜅𝜅 = 1 − 1−𝑝𝑝𝑜𝑜
1−𝑝𝑝𝑒𝑒
 , 
where 𝑝𝑝𝑒𝑒 is the baseline accuracy and 𝑝𝑝𝑜𝑜 is the scorer accuracy, such that 
𝐲𝐲 =  arg max ∑ 𝐲𝐲�𝑖𝑖∙𝜿𝜿𝑖𝑖6𝑖𝑖=1
∑ 𝜿𝜿𝑖𝑖
6
𝑖𝑖=6
    (1) 
In this implementation, scorers with a higher consensus with the group are considered more reliable 
and have their assessments weighted heavier than the rest. This also avoided split decisions on 
end-results.  
 
Optimizing machine learning performance for sleep staging 
We next explored how various machine learning algorithms (see Methods) performed depending on 
cohort, memory (i.e. feed forward (FF) versus long short-term memory networks (LSTM)), signal 
segment length (short segments of 5 s (SS) versus long segments of 15 s (LS)), complexity (i.e. low 
(SH) vs. high (LH)), encoding (i.e. octave versus cross correlation (CC) encoding, and realization 
type (repeated training sessions). The performance of these machine learning algorithms was 
compared with the six-scorer consensus in the IS-RC and with single scorer data in 3 other cohorts, 
the Stanford Sleep Cohort (SSC)10,32, the Wisconsin Sleep Cohort (WSC)32,33 and the Korean 
Hypersomnia Cohort (KHC)10,34 (see datasets section in Methods for description of each cohort).  
 
Model accuracy varies across datasets, reflecting the fact scorer performance may be different 
across sites, and because unusual subjects such as those with specific pathologies can be more 
difficult to score—a problem affecting both human and machine scoring. In this study, the worst 
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performance was seen in the KHC and SSC with narcolepsy, and the best performance was 
achieved on IS-RC data (Supplementary Figure 1 a, Table 2, Supplementary Table 7). The 
SSC+KHC cohorts mainly contain patients with more fragmented sleeping patterns, which would 
explain a reduced performance. The IS-RC has the most accurate label, minimizing the effects of 
erroneous scoring, which therefore leads to an increased performance. Incorporating large 
ensembles of different models increased mean performance slightly (Table 2).  
 
The two most important factors that increased prediction accuracy were encoding and memory, while 
segment length, complexity and number of realizations were less important (Supplementary Figure 
1). The effect of encoding was less prominent in the IS-RC. Prominent factor interactions include 
(Supplementary Figure 2): (i) CC encoding models improve with higher complexity, whereas octave 
encoding models worsen; (ii) increasing segment length positively affects models with low 
complexity, but does not affect models with a high complexity; and (iii) adding memory improves 
models with an octave encoding more than models with a CC encoding. Because the IS-RC data is 
considered the most reliable, we decided to use this data as benchmark for model comparison. This 
standard improved as more scorers were added, and the model performance increased. (Figure 1 
a). The different model configurations described in this section do not represent exhaustive 
configuration search, and future work experiments might result in improved results. 
 
Figure 2 a displays typical scoring outputs (bottom panels) obtained with a single sleep study of the 
IS-RC cohort in comparison to 6 scorer consensus (top panel).  The model results are displayed as 
hypnodensity graphs, representing not only discrete sleep stage outputs, but the probability of 
occurrence of each sleep state for each epoch (See definition in data Labels, scoring and fuzzy 
logic). As can be seen, all models performed well, and segments of the sleep study with the lowest 
scorer consensus (top) are paralleled by similar sleep stage probability uncertainty, with performance 
closest to scoring consensus achieved by an ensemble model described below (second to top). 
 
Final implementation of automatic sleep scoring algorithm  
Because of model noise, potential inaccuracies, and the desire to quantify uncertainty, the final 
implementation of our sleep scoring algorithm is an ensemble of different CC models with small 
variations in model parameters, such as the number of feature-maps and hidden nodes. This was 
achieved by randomly varying the parameters between 50% and 150% of the original values using 
the CC/SH/LS/LSTM as a template (this model achieved similar performance to the CC/LH/LS/LSTM 
while requiring significantly less computational power).   
 
All models make errors, but as these errors occur independently of each other, the risk of not 
detecting and correcting errors falls with increasing model numbers. For this reason, 16 such models 
were trained, and at each analyzed segment both mean and variance of model estimates were 
calculated. As expected, the relative model variance (standardized to the average variance in a 
correct wakefulness prediction) is generally lower in correct predictions (Supplementary Table 3) and 
this can be used to inform users about uncertain/incorrect estimates. To demonstrate the 
effectiveness of this final implementation, the average of the models is shown alongside the 
distribution of 5234±14 scorers on 150 epochs, a dataset provided by the AASM (AASM inter-scorer 
reliability (ISR) dataset, (see datasets section in Methods). On these epochs, the AASM ISR 
achieved a 90% agreement between scorers. In comparison, the model estimates reached a 95% 
accuracy compared to the AASM consensus (Figure 2 b). Using the model ensemble and reporting 
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on sleep stage probabilities and inter-model variance for quality purpose constitute the core of our 
sleep scoring algorithm. 
 
Ensemble/Best model performance 
Supplementary Table 2 reports on concordance for our best model, the ensemble of all CC models.  
Concordance is presented in a weighted and un-weighted manner, between the best model estimate, 
and scorer consensus (Table 3). Weighing of a segment was based on scorer confidence and serves 
to weigh down controversial segments. For each recording 𝑖𝑖, the epoch-specific weight 𝜔𝜔𝑛𝑛 and 
weighted accuracy 𝛼𝛼𝜔𝜔 were calculated as: 
𝜔𝜔𝑛𝑛 = max
𝑧𝑧∈𝒵𝒵
(𝐏𝐏(𝐲𝐲𝑛𝑛|𝐱𝐱𝑛𝑛)𝑧𝑧) − ℓ𝒵𝒵2�𝐏𝐏(𝐲𝐲𝑛𝑛|𝐱𝐱𝑛𝑛)�    (2) 
𝛼𝛼𝜔𝜔
(𝑖𝑖) = 1
∑ 𝜔𝜔𝑛𝑛𝑛𝑛
∑ 𝜔𝜔𝑛𝑛 ∙𝑛𝑛 �arg max
𝑚𝑚∈ℳ
�𝐏𝐏𝑚𝑚(𝒚𝒚�𝑛𝑛|𝐱𝐱𝑛𝑛)� ∩ arg max
𝑧𝑧∈𝒵𝒵
�𝐏𝐏𝑧𝑧(𝐲𝐲𝑛𝑛|𝐱𝐱𝑛𝑛)��   (3) 
where ℓ𝒵𝒵2 �𝐏𝐏(𝐲𝐲𝑛𝑛|𝐱𝐱𝑛𝑛)� is the second most likely stage assessed by the set of scorers (experts) denoted 
by 𝒵𝒵, of the 𝑛𝑛th epoch in a sleep recording. As with scorers, the biggest discrepancies occurred 
between wake versus N1, N1 versus N2 and N2 versus N3. Additionally, the weighted performance 
was almost universally better than the un-weighted performance, raising overall accuracy from 87% 
to 94%, indicating a high consensus between automatic scoring and scorers in places with high 
scorer-confidence. An explanation for these results could be that both scorers and model are forced 
to make a choice between two stages when data is ambiguous. An example of this may be seen in 
Figure 2 a. Between hours 1 and 3 several bouts of N3 occur, although they often do not reach the 
threshold for being the most likely stage. As time progresses, more evidence for N3 appears 
reflecting increased proportion of slow waves per epoch, and confidence increases, which finally 
yields “definitive” N3. This is seen in both model and scorer estimates. Choosing to present the data 
as hypnodensity graphs mitigates this problem. The various model estimates produce similar results, 
which also resemble the scorer assessment distribution, although models without memory fluctuate 
slightly more, and tend to place a higher probability on REM sleep in periods of wakefulness, since 
no contextual information is provided. 
 
Influences of sleep pathologies 
As seen in Table 2, the different cohorts achieve different performances. To see how much may be 
attributed to various pathologies, five different ANOVAs were made, with accuracy as the dependent 
variable, using cohort, age (grouped as age<30, 30≤age<50 and age≥50) and sex as covariates 
(Supplementary Table 4), investigating the effect of insomnia, OSA, Restless Leg Syndrome (RLS), 
Periodic Leg Movement Index (PLMI) and T1N on accuracy of our machine learning routine versus 
human scoring. This was performed in the cohort mentioned above with addition of the Austrian 
Hypersomnia Cohort (AHC)35. The p-values obtained from paired t-testing for each condition were 
0.75 (insomnia), 7.53×10-4 (OSA), 0.13 (RLS), 0.22 (PLMI) and 1.77×10-15 (T1N) respectively, 
indicating that only narcolepsy had a strong effect on scorer performance. Additionally, in the context 
of narcolepsy cohort and age yielded p-values between 3.69×10-21 and 2.81×10-82, and 0.62 and 
6.73×10-6, respectively. No significant effect of gender was ever noted. Cohort effects were expected 
and likely reflect local scorer performances and differences in PSG hardware and filter setups at 
every site. Decreased performance with age likely reflects decreased EEG amplitude, notably in 
N3/slow wave sleep amplitude with age36. 
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Resolution of sleep stage scoring 
Epochs are evaluated with a resolution of 30 seconds, an historical standard that is not founded in 
anything physiological, and limits the analytical possibilities of a hypnogram. Consequently, it was 
examined to what extent the performance would change as a function of smaller resolution. Only the 
models using a segment size of 5 seconds were considered. Segments were averaged to achieve 
performances at 5, 10, 15 and 30 second resolutions, and the resulting performances in terms of 
accuracy are shown in Figure 1 b. Although the highest performance was found using a resolution 
of 30 seconds, performance dropped only slightly with decreasing window sizes.  
 
Construction and evaluation of a narcolepsy biomarker 
The neural networks produce outputs that depend on evidence in the input data for or against a 
certain sleep stage based on features learned through training. We hypothesized that narcolepsy, a 
condition characterized by sleep/wake stage mixing/dissociation37–41, would result in a greater than 
normal overlap between stages, an observation that was obvious when sleep stage probability were 
plotted in such subjects (see example in Figure 3). Based on this result, we hypothesized that such 
sleep stage model outputs could be used as a biomarker for the diagnosis of narcolepsy using a 
standard nocturnal PSG rather than the more time consuming MSLT.   
 
To quantify narcolepsy-like behavior for a single recording, we generated features quantifying sleep 
stage mixing/dissociation. These are based on descriptive statistics and other features describing 
persistence of a set of new time series generated from the geometric mean of every permutation of 
the set of sleep stages, as obtained from the 16 CC sleep stage prediction models. 
  
In addition to this, we also added features expected to predict narcolepsy based on prior work, such 
as REM sleep latency and sleep stage sequencing parameters (see hypnodensity as feature for the 
diagnosis of T1N section in Methods for details).  A recursive feature elimination (RFE) procedure42 
was performed on extracted features with average outcome putting the optimal number of relevant 
features at 38. An optimal selection frequency cut-off of 0.40 (i.e. including a feature if it was selected 
40% of the time) was determined using a cross-validation setup on the training data. Features are 
described in Supplementary Table 5 with detailed description of the 8 most important features 
reported in Table 4. 
Final predictions were achieved by creating a separate Gaussian Predictor (GP) narcolepsy classifier 
from each of the sleep scoring models used in the final implementation. This was tested in seven 
independent datasets: a training dataset constituted of PSG from WSC32,33, SSC10,32, KHC10,34, 
AHC35, Jazz Clinical Trial Sample (JCTS) 43, Italian Hypersomnia Cohort (IHC)41, and DHC; with 
verification in test data mostly constituted of PSG from the same cohorts and independent replication 
in the French Hypersomnia Cohort (FHC), and the Chinese Narcolepsy Cohort (CNC)12, that had 
never been seen by the algorithm (see Supplementary Table 1). The algorithm produced values 
between -1 and 1, with 1 indicating a high probability of narcolepsy. A cut-off threshold between 
narcolepsy type 1 and “other“ was set at -0.03 (red dot, Figure 4), determined using training data, as 
shown in Figure 4 a. The optimal trade-off achieves both high sensitivity and specificity, which is 
seen to translate well onto the test data (Figure 4 b) and the never seen replication sample (Figure 
4 c).  
In the training data, a sensitivity of 94% and specificity of 96% were achieved, and in the testing data 
a sensitivity of 91% and specificity of 96% were achieved, while the sensitivity and specificity for the 
replication sample were 93% and 91%, respectively. When HLA was added to this model (Figure 4 
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d-f), the sensitivity became 90% and the specificity rose to 99%, and an updated cut-off threshold of 
-0.53 was determined (green dot, Figure 4 d-f). Furthermore, in the high pre-test sample we obtained 
a sensitivity and specificity of 90% and 92%, which rose to 90% and 98% when adding HLA. More 
descriptive statistics including 95% confidence intervals are found in Supplementary Table 6.  
 10 
DISCUSSION 
 
In recent years, machine learning has been used to solve similar or more complex problems, such 
as labeling images, understanding speech, and translating language, and have seen advancement 
to the point where humans are now sometimes outperformed21–23, while also showing promising 
results in various medical fields24–29. Automatic classification of sleep stages using automatic 
algorithms is not novel44,45, but only recently has this type of machine learning been applied and the 
effectiveness has only been demonstrated in a small numbers of sleep studies46–49. Because PSGs 
contain large amounts of manually annotated “gold standard” data, we hypothesized this method 
would be ideal to automatize sleep scoring. We have shown, that machine learning can be used to 
score sleep stages in PSGs with high accuracy in multiple physical locations in various recording 
environments, using different protocols and hardware/software configurations, and in subjects with 
and without various sleep disorders.  
 
After testing various machine learning algorithms with and without memory and specific encodings, 
we found increased robustness using a consensus of multiple algorithms in our prediction. The main 
reason for this is likely the sensitivity of each algorithm to particular aspects of each individual 
recording, resulting in increased or decreased predictability. Supplementary Figure 1 b displays the 
correlations between different models. Models that incorporate an ensemble of different models 
generally have a higher overall correlation coefficient than singular models, and since individual 
models achieve similar performances, it stands to reason that these would achieve the highest 
performance. One potential source for this variability was, in addition to the stochastic nature of the 
training, the fact recordings were conducted in different laboratories that were using different 
hardware and filters, and had PSGs scored by technicians of various abilities. Another contributor 
was the presence of sleep pathologies in the dataset that could influence machine learning. Of the 
pathologies tested, only narcolepsy had a very significant effect on the correspondence between 
manual and machine learning methods (p=1.77x10-15 vs p= 7.53x10-4 for sleep apnea for example) 
(Supplementary Table 4 and 7). This was not surprising as the pathology is characterized by unusual 
sleep stage transitions, for example transitions from wake to REM sleep, which may make human 
or machine learning staging more difficult. This result suggests that reporting inter-model variations 
in accuracy for each specific patient has value in flagging unusual sleep pathologies, so this metric 
is also reported by our detector.  
 
Unlike previous attempts using automatic detector validations, we were able to include 70 subjects 
scored by six technicians in different laboratories (the IS-RC cohort)31 to independently validate our 
best automatic scoring consensus algorithm. This allowed us to estimate the performance at 87% in 
comparison to the performance of a consensus score for every epoch amongst six expert technicians 
(ultimate gold standard) (Table 1). Including more scorers produces a better gold standard, and as 
Figure 1 a indicates, the model accuracy also increases with more scorers. Naturally, extrapolating 
from this should be done with caution, however it is reasonable to assume that the accuracy would 
continue to increase with increased scorers. In comparison, performance of any individual scorer 
range from 74% to 85% when compared to the same six scorer gold standard, keeping in mind this 
performance is artificially inflated since the same scorers evaluated are included in the gold standard 
(unbiased performance of any scorer versus consensus of remaining 5 scorers range from 69-80%. 
The best model achieves 87% accuracy using 5 scorers (Figure 1 a and Table 1), and is statistically 
higher than all scorers. As with human scorers, the biggest discrepancies in machine learning 
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determination of sleep stages occurred between wake versus N1, N1 versus N2 and N2 versus N3. 
This is logical as these particular sleep stage transitions are part of a continuum, artificially defined 
and subjective. To give an example: an epoch comprised of 18% slow wave activity is considered 
N2 while an epoch comprised of 20% slow wave activity qualifies as N3. Overall, data indicate that 
our machine learning algorithm performs better than individual scorers, as typically used in clinical 
practice, or similar to the best of 5 scorers in comparison to a combination of 5 experts scoring each 
epoch by consensus. It is also able to score at higher resolution, i.e. 5 seconds, making it 
unnecessary to score sleep stages by 30 second epochs, an outdated rule dating from the time sleep 
was scored on paper. Although the data sample used for multi-scorer validation contained only 
female subjects, the scoring accuracy of our model was not seen to be affected by gender 
(Supplementary Table 3) in another analysis. 
Using our models, and considering how typical T1N behaved in our sleep stage machine learning 
routines, we extracted features that could be useful to diagnose this condition. T1N is characterized 
by the a loss of hypocretin-producing cells in the hypothalamus3 and can be best diagnosed by 
measuring hypocretin levels in the CSF11, a procedure that requires a lumbar puncture, a rarely 
performed procedure in the US. At the symptomatic level, T1N is characterized by sleepiness, 
cataplexy (episodes of muscle weakness during wakefulness triggered by emotions) and numerous 
symptoms reflecting poor nocturnal sleep (insomnia) and symptoms of "dissociated REM sleep".    
Dissociated REM sleep is reflected by the presence of unusual states of consciousness where REM 
sleep is intermingled with wakefulness, producing disturbing reports of dreams that interrupt 
wakefulness and seem real (dream-like hallucinations), or episodes where the sleeper is awake but 
paralyzed as in normal REM sleep (sleep paralysis). The current gold standard for T1N diagnosis is 
the presence of cataplexy and a positive MSLT. In a recent large study of the MSLT, specificity and 
sensitivity for T1N were 98.6% and 92.9% in comparing T1N versus controls, and 71.2% and 93.4% 
in comparing T1N versus other hypersomnia cases (high pre-test probability cohort)10. 
Table 4 and Supplementary Table 5 reveal features found in nocturnal PSGs that discriminate type 
1 narcoleptics and non-narcoleptics. One of the most prominent features, short latency REM sleep, 
bears great resemblance to the REM sleep latency, which is already used clinically to diagnose 
narcolepsy, although in this case it is calculated using fuzzy logic and thus represent a latency where 
accumulated sleep is suggestive of a high probability of REM sleep having occurred (as opposed to 
a discrete REM latency scored by a technician). A short REM latency during nocturnal PSG (typically 
15 minutes) has recently been shown to be extremely specific (99%) and moderately sensitive (40-
50%) for T1N10,50. The remaining selected features also describe a generally altered sleep 
architecture, particularly between REM sleep, light sleep and wake, aspects of narcolepsy already 
known and thus reinforcing their validity as biomarkers.  
For example, the primary feature as determined by the RFE algorithm was the time taken until 5% 
of the accumulated sum of the geometric mean between stages W, N2 and REM had been reached 
(see also Table 4), which reflects the uncertainty between wakefulness, REM and N2 sleep at the 
beginning of the night. Specifically, for the 𝑖𝑖th epoch, the model will output probabilities for each sleep 
stage, and the sum of the geometric mean 𝜋𝜋(𝑖𝑖) is calculated as 
𝜋𝜋(𝑖𝑖) = 𝑝𝑝(W) × 𝑝𝑝(N2) + 𝑝𝑝(W) × 𝑝𝑝(REM) + 𝑝𝑝(N2) × 𝑝𝑝(REM)   (4) 
The feature value is then calculated as the time it takes in minutes for the accumulated sum of 𝜋𝜋(𝑖𝑖)’s 
to reach 5% of the total sum ∑ 𝜋𝜋(𝑖𝑖)𝑖𝑖 . Since each of the geometric means in 𝜋𝜋(𝑖𝑖) reflects the staging 
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uncertainty between each sleep stage pair, 𝜋𝜋(𝑖𝑖) alone reflects the general sleep stage uncertainty 
for that specific epoch as predicted by the model. A very high value will be attained for epoch 𝑖𝑖 if the 
probability for N2, W, and REM are equally probable with probabilities for the remaining sleep stages 
being low or close to zero. A PSG with a high staging uncertainty between sleep and wake early in 
the night would reach the 5% threshold rapidly. 
Using these features, we were able to determine an optimal cut off that discriminated narcolepsy 
from controls and any other patients with as high specificity and sensitivity as the MSLT 
(Supplementary Table 6), notably when HLA typing is added. This is true for both the test and the 
never seen replication samples. Although we do observe a small drop in specificity in the replication 
sample, the efficacy of the detector was also tested in the context of naïve patients with hypersomnia 
(high pre-test probability sample), and performance found to be similar to the MSLT. 
MSLT testing requires that patients spend an entire night and day in a sleep laboratory. The use of 
this novel biomarker could reduce time spent to a standard 8-hour night recording, as done for the 
screening of other sleep pathologies (e.g. OSA), allowing improved recognition of T1N cases at a 
fraction of the cost. A positive predictive value could also be provided depending of the nature of the 
sample and known narcolepsy prevalence (low in general population screening, intermediary in 
overall clinic population sample, and high in hypersomnia cohorts). It also opens the possibility of 
using home sleep recordings for diagnosing narcolepsy. In this direction, because of the probabilistic 
and automatic nature of our biomarker, estimates from more than one night could be automatically 
analyzed and combined over time, ensuring improved prediction. However, it is important to note, 
that this algorithm will not replace the MSLT in the ability to predict excessive daytime sleepiness 
through the measure of mean sleep latency across daytime naps, which is an important 
characteristic of other hypersomnias. 
In conclusion, models which classify sleep by assigning a membership function to each of five 
different stages of sleep for each analyzed segment were produced, and factors contributing to the 
performance were analyzed. The models were evaluated on different cohorts, one of which 
contained 70 subjects scored by six different sleep scoring technicians, allowing for interscorer 
reliability assessments. The most successful model, consisting of an ensemble of different models, 
achieved an accuracy of 87% on this dataset, and was statistically better performing than any 
individual scorer.  It was also able to score sleep stages with high accuracy at lower time resolution 
(5 seconds), rendering the need for scoring per 30 seconds epoch obsolete. When predictions 
were weighted by the scorer agreement, performance rose to 95%, indicating a high consensus 
between the model and human scorers in areas of high scorer agreement. A final implementation 
was made using an ensemble with small variations of the best single model. This allowed for better 
predictions, while also providing a measure of uncertainty in an estimate. 
When the staging data was presented as hypnodensity distributions, the model conveyed more 
information about the subject than through a hypnogram alone. This led to the creation of a biomarker 
for narcolepsy that achieved similar performance to the current clinical gold standard, the MSLT but 
only requires a single sleep study. If increased specificity is needed, for example in large-scale 
screening, HLA or additional genetic typing brings specificity above 99% without loss of sensitivity. 
This presents an option for robust, consistent, inexpensive and simpler diagnosis of subjects who 
may have narcolepsy, as such tests may also be carried out in a home environment. 
This study shows how hypnodensity graphs can be created automatically from raw sleep study data, 
and how the resulting interpretable features can be used to generate a diagnosis probability for T1N. 
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Another approach would be to classify narcolepsy directly from the neural network by optimizing the 
performance not only for sleep staging, but also for direct diagnosis by adding an additional softmax 
output, thereby creating a multitask classifier. This approach could lead to better predictions, since 
features are not then limited to by a designer imagination. A drawback of this approach is that 
features would no longer be as interpretable and meaningful to clinicians. If meaning could be 
extracted from these neural network generated features, this might open the door to a single 
universal sleep analysis model, covering multiple diseases. Development of such a model would 
require adding more subjects with narcolepsy and other conditions to the pool of training data. 
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METHODS 
 
Datasets 
The success of machine learning depends on the size and quality of the data on which the model is 
trained and evaluated51,52. We used a large dataset comprised of several thousand sleep studies to 
train, validate, and test/replicate our models. To ensure significant heterogeneity, data came from 10 
different cohorts recorded at 12 sleep centers across 3 continents: SSC10,32, WSC32,33, IS-RC31, 
JCTS43, KHC10,34, AHC35, IHC41, DHC53, FHC, and CNC12. Institutional Review Boards approved the 
study and informed consent was obtained from all participants. Technicians trained in sleep scoring 
manually labeled all sleep studies. Figure 5 a, b, and c summarize the overall design of the study for 
sleep stage scoring and narcolepsy biomarker development. Supplementary Table 1 provides a 
summary of the size of each cohort and how it was used. In the narcolepsy biomarker aspect of the 
study, PSGs from T1N and other patients were split across most datasets to ensure heterogeneity 
in both the training and testing dataset. For this analysis, a few recordings with poor quality sleep 
studies, i.e. missing critical channels, with additional sensors or with a too short sleep duration (≤ 2 
hours) were excluded. A “never seen” subset cohort that included French and Chinese subjects (FHC 
and CNC) was also tested.  Below is a brief description of each dataset. 
 
Population-based Wisconsin Sleep Cohort 
This cohort is a longitudinal study of state agency employees aged 37 - 82 years from Wisconsin, 
and approximates a population-based sample (see Supplementary Table 1 for age at study) and are 
generally more overweight33. The study is ongoing, and dates to 1988. 2167 PSGs in 1086 subjects 
were used for training while 286 randomly selected PSGs were used for validation testing of the 
sleep stage-scoring algorithm and narcolepsy biomarker training. Approximately 25% of the 
population have an Apnea Hypopnea Index (AHI) above 15/hour and 40% have a PLMI above 15/hr. 
A detailed description of the sample can be found in Young33 and Moore et al.32. The sample does 
not contain any T1N patients, and the three subjects with possible T1N were removed54.  
 
Patient-based Stanford Sleep Cohort 
PSGs from this cohort were recorded at the Stanford Sleep Clinic dating back to 1999, and represent 
sleep disorder patients aged 18-91 visiting the clinic (see Supplementary Table 1 for age at study). 
The cohort contains thousands of PSG recordings, but for this study we used 894 diagnostic (no 
positive airway pressure (PAP)) recordings in independent patients that have been used in prior 
studies30. This subset contains patients with a range of different diagnoses including: sleep 
disordered breathing (607), insomnia (141), REM sleep behavior disorder (4), restless legs 
syndrome (23), T1N (25), delayed sleep phase syndrome (14), and other conditions (39). Description 
of the subsample can be found in Andlauer et al.10 and Moore et al.32. Approximately 30% of subjects 
have an AHI above 15/hour, or a PLMI above 15/hour. 617 randomly selected subjects were used 
for training the neural networks while 277 randomly selected PSGs were kept for validation testing 
of the sleep stage scoring algorithm. These 277 subjects were also used for training the narcolepsy 
biomarker algorithm. The sample contains PSGs of 25 independent untreated subjects with T1N (12 
with low CSF hypocretin-1, the others with clear cataplexy). 26 subjects were removed from the 
study—4 due to poor data quality, and the rest because of medication use. 
 
Patient-based Korean Hypersomnia Cohort 
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The Korean Hypersomnia Cohort is a high pretest probability sample for narcolepsy. It includes 160 
patients with a primary complaint of excessive daytime sleepiness (see Supplementary Table 1 for 
age at study). These PSGs were used for testing the sleep scoring algorithm and for training the 
narcolepsy biomarker algorithm. No data was used for training the sleep-scoring algorithm. Detailed 
description of the sample can be found in Hong et al.34 and Andlauer et al.10 The sample contains 
PSGs of 66 independent untreated subjects with T1N and clear cataplexy. Two subjects were 
removed from the narcolepsy biomarker study because of poor data quality. 
 
Patient-based Austrian Hypersomnia Cohort 
Patients in this cohort were examined at the Innsbruck Medical University in Austria as described in 
Frauscher et al.35. The AHC contains 118 PSGs in 86 high pretest probability patients for narcolepsy 
(see Supplementary Table 1 for details). 42 patients (81 studies) are clear T1N with cataplexy cases, 
with all but 3 having a positive MSLT (these three subjects had a mean sleep latency (MSL)>8 
minutes but multiple SOREMPs). The rest of the sample has idiopathic hypersomnia and type 2 
narcolepsy. Four patients have an AHI>15/hour and 25 had a PLMI>15/hour. Almost all subjects had 
two sleep recordings performed, which were kept together such that no two recordings from the 
same subject were split between training and testing partitions. 
 
Patient-based Inter-scorer Reliability Cohort 
As Rosenberg et al.16 have shown, variation between individual scorers can sometimes be large, 
leading to an imprecise gold standard. To quantify this, and to establish a more accurate gold 
standard, 10 scorers from five different institutions, University of Pennsylvania, St. Luke’s Hospital, 
University of Wisconsin at Madison, Harvard University, and Stanford University, analyzed the 
same 70 full night PSGs. For this study, scoring data from University of Pennsylvania, St. Luke’s 
and Stanford were used. All subjects are female (see Supplementary Table 1 for details). This 
allowed for a much more precise gold standard, and the inter-scorer reliability could be quantified 
for a dataset, which could also be examined by automatic scoring algorithms. Detailed description 
of the sample can be found in Kuna et al.31 and Malhotra6. The sample does not contain any T1N 
patients. 
 
The Jazz Clinical Trial Sample 
This sample includes seven baseline sleep PSGs from five sites taken from a clinical trial study of 
sodium oxybate in narcolepsy (SXB15 with 45 sites in Canada, USA, and Switzerland) conducted 
by Orphan Medical, now named Jazz Pharmaceuticals. The few patients included are those with 
clear and frequent cataplexy (a requirement of the trial) that had no stimulant or antidepressant 
treatment at baseline43. All 7 subjects in this sample were used exclusively for training the 
narcolepsy biomarker algorithm. 
 
Patient-based Italian Hypersomnia Cohort 
Patients in this high pretest probability cohort (see Supplementary Table 1 for demographics) were 
examined at the IRCCS, Istituto delle Scienze Neurologiche ASL di Bologna in Italy as described in 
Pizza et al.41. The IHC contains 70 T1N patients (58% male, 29.5± 1.9 years old), with either 
documented low CSF hypocretin levels (59 cases, all but 2 HLA DQB1*06:02 positive), or clear 
cataplexy, positive MSLTs and HLA positivity (11 subjects). As non-T1N cases with unexplained 
daytime somnolence, the cohort includes 77 other patients: 19 with idiopathic hypersomnia, 7 with 
type 2 narcolepsy and normal CSF hypocretin-1, 48 with a subjective complaint of excessive daytime 
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sleepiness not confirmed by MSLT, and 3 with secondary hypersomnia. Subjects in this cohort were 
used for training (n=87) and testing (n=61) the narcolepsy biomarker algorithm.  
Patient-based Danish Hypersomnia Cohort 
Patients in this cohort were examined at the Rigshospitalet, Glostrup, Denmark as described in 
Christensen et al53. The DHC contains 79 PSGs in controls and patients (see Supplementary Table 
1 for details). Based on PSG, multiple sleep latency test and cerebrospinal fluid hypocretin-1 
measures, the cohort includes healthy controls (19 subjects), patients with other sleep disorders and 
excessive daytime sleepiness (20 patients with CSF hypocretin-1 ≥ 110 pg/ml), narcolepsy type 2 
(22 patients with CSF hypocretin-1 ≥ 110 pg/ml), and T1N (28 patients with CSF hypocretin 1 ≤ 110 
pg/ml). All 79 subjects in this cohort were used exclusively for training the narcolepsy biomarker 
algorithm. 
 
Patient-based French Hypersomnia Cohort 
This cohort consists of 122 individual PSGs recorded at the Sleep-Wake Disorders Center, 
Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier, France (see Supplementary 
Table 1 for demographics). The FHC contains 63 subjects with T1N (all but two tested with CSF 
hypocretin-1 ≤ 110 pg/ml, five below 18 years old, 55 tested for HLA, all positive for HLA 
DQB1*06:02) and 22 narcolepsy type 2 (19 with CSF hypocretin-1 > 200 pg/ml, and three subjects 
with CSF hypocretin-1 between 110 and 200 pg/ml, three HLA positive). The remaining 36 subjects 
are controls (15 tested for HLA, two with DQB1*06:02) without other symptoms of hypersomnia. The 
FHC was used as data for the replication study of the narcolepsy biomarker algorithm. 
 
Patient-based Chinese Narcolepsy Cohort 
This cohort contains 199 individual PSGs recorded (see Supplementary Table 1 for demographics). 
The CNC contains 67 subjects diagnosed with T1N exhibiting clear-cut cataplexy (55 tested HLA 
DQB1*06:02 positive), while the remaining 132 subjects are randomly selected population controls 
(15 HLA DQB1*06:02 positive, 34 HLA negative, remaining unknown) 12. Together with the FHC, the 
CNC was used as data for the replication study of the narcolepsy biomarker algorithm. 
 
American Academy of Sleep Medicine Sleep Study 
The AASM ISR dataset is composed of a single control sleep study of 150 30 sec epochs that was 
scored by 5234±14 experienced sleep technologists for quality control purposes. Design of this 
dataset is described in Rosenberg et al.16. 
 
Data labels, scoring and fuzzy logic 
Sleep stages were scored by PSG-trained technicians using established scoring rules, as described 
in the AASM Scoring Manual7. In doing so, technicians assign each epoch with a discrete value. With 
a probabilistic model, like the one proposed in this study, a relationship to one of the fuzzy sets is 
inferred based on thousands of training examples labeled by many different scoring-technicians.  
 
The hypnodensity graph refers to the probability distribution over each possible stage for each 
epoch, as seen in Figure 2 a and b. This allows more information to be conveyed, since every epoch 
of sleep within the same stage is not identical. For comparison with the gold standard, however, a 
discrete value must be assigned from the model output as: 
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𝑦𝑦� = argmax
𝐲𝐲𝑖𝑖
∑ 𝐏𝐏𝑖𝑖(𝐲𝐲𝑖𝑖|𝐱𝐱𝑖𝑖)𝑁𝑁𝑖𝑖    (5) 
Where 𝐏𝐏𝑖𝑖(𝐲𝐲𝑖𝑖|𝐱𝐱𝑖𝑖) is a vector with the estimated probabilities for each sleep stage in the 𝑖𝑖th segment, 
𝑁𝑁 is the number of segments an epoch is divided into, and 𝑦𝑦� is the estimated label.  
 
Sleep scoring technicians score sleep in 30 second epochs, based on what stage they assess is 
represented in the majority of the epoch—a relic of when recordings were done on paper. This means 
that when multiple sleep stages are represented, more than half of the epoch may not match the 
assigned label. This is evident in the fact that the label accuracy decreases near transition epochs20. 
One solution to this problem is to remove transitional regions to purify each class. However, this has 
the disadvantage of under-sampling transitional stages, such as N1, and removes the context of 
quickly changing stages, as is found in a sudden arousal. It has been demonstrated that the negative 
effects of imperfect “noisy” labels may be mitigated if a large enough training dataset is incorporated 
and the model is robust to overfitting41. This also assumes that the noise is randomly distributed with 
an accurate mean—a bias cannot be cancelled out, regardless of the amount of training data. For 
these reasons, all data including those containing sleep transitions were included. Biases were 
evaluated by incorporating data from several different scoring experts cohorts and types of subjects. 
 
To ensure quick convergence, while also allowing for long-term dependencies in memory-based 
models, the data were broken up in 5 minute blocks and shuffled to minimize the shift in covariates 
during training caused by differences between subjects. To quantify the importance of segment sizes, 
both 5 second and 15 second windows were also tested. 
 
Data selection and pre-processing 
A full night PSG involves recording many different channels, some of which are not necessary for 
sleep scoring55. In this study, EEG – C3 or C4, and O1 or O2, chin EMG, and the left and right EOG 
channels were used, with reference to the contralateral mastoid. Poor electrode connections are 
common when performing a PSG analysis. This can lead to a noisy recording, rendering it useless. 
To determine whether right or left EEG channels were used, the noise of each was quantified by 
dividing the EEG data in 5 minute segments, and extracting the Hjorth parameters56. These were 
then log-transformed, averaged, and compared with a previously established multivariate 
distribution, based on the WSC32,33 and SSC10,32 training data. The channel with lowest Mahalanobis 
distance57 to this distribution was selected. The log-transformation has the advantage of making flat 
signals/disconnects as uncommon as very noisy signals, in turn making them less likely to be 
selected. To minimize heterogeneity across recordings, and at the same time reducing the size of 
the data, all channels were down-sampled to 100 Hz. Additionally, all channels were filtered with a 
5th order two-direction infinite impulse response (IIR) high-pass filter with cutoff frequency of 0.2 Hz 
and a 5th order two-direction IIR low-pass filter with cutoff frequency of 49 Hz. The EMG signal 
contains frequencies well above 49 Hz, but since much data had been down-sampled to 100 Hz in 
the WSC, this cutoff was selected for all cohorts. All steps of the pre-processing are illustrated in 
Figure 5 a. 
 
 
Convolutional and recurrent neural networks 
Convolutional neural networks (CNN) are a class of deep learning models first developed to solve 
computer vision problems30. A CNN is a supervised classification model in which a low-level, such 
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as an image, is transformed through a network of filters and sub-sampling layers. Each layer of filters 
produces a set of features from the previous layer, and as more layers are stacked, more complex 
features are generated. This network is coupled with a general-purpose learning algorithm, resulting 
in features produced by the model reflecting latent properties of the data rather than the imagination 
of the designer. This property places fewer constrictions on the model by allowing more flexibility, 
and hence the predictive power of the model will increase as more data is observed. This is facilitated 
by the large number of parameters in such a model, but may also necessitate a large amount of 
training data. Sleep stage scoring involves a classification of a discrete time-series, in which adjacent 
segments are correlated. Models that incorporate memory may take advantage of this and may lead 
to better overall performance by evening out fluctuations. However, these fluctuations may be the 
defining trait or anomaly of some underlying pathology (such as narcolepsy, a pathology well known 
to involve abnormal sleep stages transitions), present in only a fraction of subjects, and perhaps 
absent in the training data. This can be thought of similarly to a person with a speech impediment: 
the contextual information will ease the understanding, but knowing only the output, this might also 
hide the fact that the person has such a speech impediment. To analyze the importance of this, 
models with and without memory were analyzed. Memory can be added to such a model by 
introducing recurrent connections in the final layers of the model. This turns the model into a 
recurrent neural network (RNN). Classical RNNs had the problem of vanishing or exploding 
gradients, which meant that optimization was very difficult. This problem was solved by changing the 
configuration of the simple hidden node into a LSTM cell58. Models without this memory are referred 
to as FF models. A more in-depth explanation of CNNs including application areas can be found the 
review article on deep learning by LeCun, Bengio and Hinton30 and the deep learning textbook by 
Goodfellow, Bengio and Courville (2016)59. For a more general introduction to machine learning 
concepts, see the textbook by Bishop (2006)60. 
 
Data input and transformations 
Biophysical signals, such as those found in a PSG, inherently have a low signal to noise ratio, the 
degree of which varies between subjects, and hence learning robust features from these signals 
may be difficult. To circumvent this, two representations of the data that could minimize these effects 
were selected. An example of each decomposition is shown in Figure 6 a. 
 
Octave encoding maintains all information in the signal, and enriches it by repeatedly removing the 
top half of the bandwidth (i.e. cut off frequencies of 49, 25, 12.5, 6.25, 3.125 Hz) using a series of 
low-pass filters, yielding a total of 5 new channels for each original channel. At no point is a high-
pass filter applied. Instead, the high frequency information may be obtained by subtracting lower 
frequency channels—an association the neural networks can make, given their universal 
approximator properties61. After filtration, each new channel is scaled to the 95th percentile and log 
modulus transformed: 
𝐱𝐱scaled = sign(𝐱𝐱)  ∙  log � |𝐱𝐱|𝑃𝑃95(𝐱𝐱) + 1�   (6) 
The initial scaling places 95% of the data between -1 and 1, a range in which the log modulus is 
close to linear. Very large values, such as those found in particularly noisy areas, are attenuated 
greatly. Some recordings are noisy, making the 95th percentile significantly higher than what the 
physiology reflects. Therefore, instead of the selecting the 95th percentile from the entire recording, 
the recording is separated into 50% overlapping 90 minute segments, from which the 95th percentile 
is extracted. The mode of these values is then used as a scaling reference. In general, scaling and 
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normalization is important to ensure quick convergence as well as generalization in neural networks. 
The decomposition is done in the same way on every channel, resulting in 25 new channels in total. 
 
CC encoding, using a CC function, underlying periodicities in the data are revealed while noise is 
attenuated. White noise is by definition uncorrelated; its autocorrelation function is zero everywhere 
except lag zero. It is this property that is utilized, even though noise cannot always be modeled as 
such. PSG signals are often obscured by undesired noise that is uncorrelated with other aspects of 
the signals. An example CC between a signal segment and an extended version of the same signal 
segment is shown in Supplementary Figure 5. Choosing the CC in this manner over a standard 
autocorrelation function serves two purposes: the slow frequencies are expressed better, since there 
is always full overlap between the two signals (some of this can be adjusted with the normal 
autocorrelation function using an unbiased estimate); and the change in fluctuations over time within 
a segment is expressed, making the function reflect aspects of stationarity. Because this is the CC 
between a signal and an extended version of itself, the zero lag represents the power of that 
segment, as is the case in an autocorrelation function. 
 
Frequency content with a time resolution may also be expressed using time-frequency 
decompositions, such as spectrograms or scalograms, however, one of the key properties of a CNN 
is the ability to detect distinct features anywhere in an input, given its property of equivariance62. A 
CC function reveals an underlying set of frequencies as an oscillation pattern, as opposed to a 
spectrogram, where frequencies are displayed as small streaks or spots in specific locations, 
corresponding to frequencies at specific times. The length and size of each CC reflects the expected 
frequency content and the limit of quasi-stationarity (i.e. how quickly the frequency content is 
expected to change). 
 
The EOG signal reveals information about eye movements such as REMs, and to some extent EEG 
activity6,7. In the case of the EOG signal, the relative phase between the two channels is of great 
importance to determine synchronized eye movements, and hence a CC of opposite channels (i.e. 
either the extended or zero padded signal is replaced with the opposite channel) is also included. 
The slowest eye-movements happen over the course of several seconds6,7, and hence a segment 
length of 4 seconds was selected for the correlation functions. To maintain resolution flexibility with 
the EEG, an overlap of 3.75 seconds was chosen. 
 
In the case of the EMG signal, the main concern is the signal amplitude and the temporal resolution, 
not the actual frequencies. As no relevant low frequency content is expected, a segment length of 
0.4 seconds and an overlap of 0.25 seconds was selected. 
 
As with the octave encoding, the data is scaled, although only within segments: 
𝐷𝐷𝑖𝑖 =  𝛾𝛾𝐱𝐱𝑖𝑖𝐲𝐲𝑖𝑖∙log (1+max (�𝛾𝛾𝐱𝐱𝑖𝑖𝐲𝐲𝑖𝑖�)max (|𝛾𝛾𝐱𝐱𝑖𝑖𝐲𝐲𝑖𝑖|)      (7) 
where 𝐷𝐷𝑖𝑖 is the scaled correlation function and 𝛾𝛾𝐱𝐱𝑖𝑖𝐲𝐲𝑖𝑖 is the unscaled correlation function. 
 
Architectures of applied CNN models  
The architecture of a CNN typically reflects the complexity of the problem that is being solved and 
how much training data is available, as a complex model has more parameters than a simple model, 
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and is therefore more likely to over-fit. However, much of this may be solved using proper 
regularization. Another restriction is the resources required to train a model—deep and complex 
models require far more operations and will therefore take longer to train and operate. In this study, 
no exhaustive hyper-parameter optimization was carried out. The applied architectures were chosen 
on the basis of other published models63. Since the models utilized three separate modalities (EEG, 
EOG and EMG), three separate sub-networks were constructed. These were followed by fully 
connected layers combining the inputs from each sub-network, which were passed onto a softmax 
output (Figure 6 b, Supplementary Figure 3). Models that utilize memory have fully connected hidden 
units replaced with LSTM cells and recurrent connections added between successive segments. 
Networks of two different sizes are evaluated to quantify the effect of increasing complexity.  
 
Training of CNN models 
Training the models involves optimizing parameters to minimize a loss function evaluated across a 
training dataset. The loss function was defined as the cross-entropy with L2 regularization: 
𝐿𝐿(𝛚𝛚) = 1
𝑁𝑁
∑ 𝐻𝐻(𝐲𝐲𝑖𝑖 , 𝐲𝐲�𝑖𝑖)𝑁𝑁𝑖𝑖=1 + 𝐿𝐿2 = 1𝑁𝑁∑ 𝐲𝐲𝑖𝑖 log 𝐲𝐲�𝒊𝒊 + (1 − 𝐲𝐲𝑖𝑖)log (1 − 𝐲𝐲�𝒊𝒊)𝑁𝑁𝑖𝑖=1  + 𝜆𝜆 ‖𝛚𝛚‖22   (8) 
where 𝐲𝐲𝑖𝑖 is the true class label of the 𝒊𝒊th window, 𝐲𝐲�𝒊𝒊 is the estimated probability of the 𝒊𝒊th window, 𝛚𝛚 
is the parameter to be updated, and 𝜆𝜆 is the weight decay parameter set at 0.00001. The model 
parameters were initialized with 𝑁𝑁(0,0.01), and trained until convergence using stochastic gradient 
decent with momentum64. Weight updates were done as: 𝛚𝛚𝑡𝑡+1 = 𝛚𝛚𝑡𝑡 + 𝜂𝜂𝐯𝐯𝑡𝑡+1 with 𝐯𝐯𝑡𝑡+1 = 𝛼𝛼𝐯𝐯𝑡𝑡 − 𝛿𝛿𝐄𝐄𝛿𝛿𝛚𝛚𝑡𝑡 
where 𝛼𝛼 is the momentum set at 0.9, 𝐯𝐯𝑡𝑡 is the learning velocity, initialized at 0, and 𝜂𝜂  is the learning 
rate, initially set at 0.005. The learning rate was gradually reduced with an exponential decay 𝜂𝜂 = 𝜂𝜂0 ∙ e−𝑡𝑡/𝜏𝜏 where t is the number of updates and 𝜏𝜏 is a time constant, here set to 12,000. 
 
Over-fitting was avoided using a number of regularization techniques, including batch 
normalization65, weight decay66, and early stopping67. Early stopping is accomplished by scheduling 
validation after every 50th training batch. This is done by setting aside 10% of the training data. 
Training is stopped if the validation accuracy starts to decrease, as a sign of over-fitting. For LSTM 
networks, dropout68 was included, set at 0.5 while training. This ensured that model parameters 
generalized to the validation data and beyond. During training, data-batches were selected at 
random. Given the stochastic nature of the training procedure, it was likely that two realizations of 
the same model would not lead to the same results, since models end up in different local minima. 
To measure the effect of this, two realizations were made of each model. 
 
Apart from model realizations, we also investigated the effect of ensembling our sleep stage 
classification model. In general, ensemble models can yield higher predictive performance than any 
single model by attacking a classification or regression problem from multiple angles. For our specific 
use case, this resolves into forming a sleep stage prediction based on the predictions of all the 
models in the given ensemble. We tested several ensembles containing various numbers of model 
architectures and data encodings, as described in Supplementary Table 8.  
 
Performance comparisons of generated CNN models 
As stated, the influences of many different factors were analyzed. These included: using octave or 
CC encoding, short (5 s) or long (15 s) segment lengths, low or high complexity, with or without 
LSTM, and using a single or two realizations of a model. To quantify the effect of each, a 25-factorial 
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experiment was designed. This lead to 32 different models (Supplementary Table 8). Comparison 
between models was done on a per epoch basis.  
 
Hypnodensity as feature for the diagnosis of T1N 
To quantify narcolepsy-like behavior for a single recording 𝑖𝑖, features were generated based on the 
geometric mean of every permutation of the set of sleep stages, 𝒮𝒮 = {W, REM, N1, N2, N3}, such that 
𝚽𝚽(𝓒𝓒𝑘𝑘) = ∏ 𝑷𝑷(𝓬𝓬 | 𝐱𝐱),𝒸𝒸∈𝒞𝒞𝑘𝑘  𝑃𝑃 ∈ [0, 1]    (9) 
where 𝚽𝚽𝑛𝑛,𝑘𝑘(𝑖𝑖)  is the geometric mean, or proto-feature, for the 𝑛𝑛th segment in recording 𝑖𝑖, 𝓢𝓢𝑘𝑘 is the k-
combination of 𝓢𝓢, and 𝓈𝓈 is a single element in 𝓢𝓢𝑘𝑘 . For 𝑘𝑘 = 1, … , 5, there exist 31 different 𝒮𝒮𝑘𝑘, e.g. 
{Wake, REM}, {N1, N2, N3} etc., as shown in Supplementary Table 9. 𝑷𝑷𝑛𝑛
(𝑖𝑖)is the predicted probability 
of a 5, 15, or 30 s epoch belonging to a certain class in 𝓢𝓢, given the data 𝐱𝐱𝑛𝑛
(𝑖𝑖). For every value of 𝑘𝑘, 
fifteen features based on the mean, derivative, entropy and cumulative sum were extracted, as 
shown in Supplementary Table 10.  
 
Additional Features for T1N Diagnosis 
In addition to above, another set of features reflecting abnormal sleep stage sequencing in T1N was 
investigated.  
 
One set of such features was selected because they have been found to differentiate T1N from other 
subjects in prior studies37,69–72. These include: nocturnal sleep REM latency (REML) 10, presence of 
a nightly SOREMP (REML ≤15 minutes)10, presence and number of SOREMPs during the night 
(SOREMPs defined as REM sleep occurring after at least 2.5 minutes of wake or stage 1), nocturnal 
sleep latency (a short sleep latency is common in narcolepsy)37. Other features include a NREM 
Fragmentation index described in Christensen et al.37 (N2 and N3 combined to represent 
unambiguous NREM and N1 and wake combined to denote wake, NREM fragmentation defined as 
22 or more occurrences where sustained N2/N3 (90 seconds) is broken by at least 1 minute of 
N1/Wake), and the number of W/N1 hypnogram bouts as defined by Christensen et al.37 (N1 and 
wake combined to indicate wakefulness and a long period defined as 3 minutes or more) In this 
study we also explore: the cumulative wake/N1 duration for wakefulness periods shorter than 15 
minutes; Cumulative REM duration following wake/N1 periods longer than 2.5 minutes; and total 
nightly SOREMP duration defined as the sum of REM epochs following 2.5 minutes W/N1 periods.  
 
Another set of 9 features reflecting hypnodensity sleep stage distribution was also created as follows. 
As noted in Supplementary Figure 4 stages of sleep accumulate, forming peaks. These peaks were 
then used to create 9 new features based on the order of the peaks, expressing a type of transition 
(W to N2, W to REM, REM to N3 etc.). If the height of the 𝑛𝑛th peak is denoted as 𝜑𝜑𝑛𝑛, the transition 
value 𝜏𝜏 is calculated as the geometric mean between successive peaks: 
𝜏𝜏𝑛𝑛 =  �𝜑𝜑𝑛𝑛 ∙ 𝜑𝜑𝑛𝑛+1   (10) 
Due to their likeness, W and N1 peaks were added to form a single type. All transitions of a certain 
type were added together to form a single feature. A lower limit of 10 was imposed on peaks to avoid 
spurious peaks. If two peaks of the same type appeared in succession the values were combined 
into a single peak. 
 
Gaussian process models for narcolepsy diagnosis 
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To avoid overfitting, and at the same time produce interpretable results, a recursive feature 
elimination (RFE) algorithm was employed, as described in Guyon (2002)42. Post-screening, the 
most optimal features (n=38) were used in a GP classifier as described below. GP classifiers are 
non-parametric probabilistic models that produce robust non-linear decision boundaries using 
kernels, and unlike many other classification tools, provide an estimate of the uncertainty. This is 
useful when combining estimates, but also when making a diagnosis; if an estimate is particularly 
uncertain, a doctor may opt for more tests to increase certainty before making a diagnosis. In a GP, 
a training data set is used to optimize a set of hyper-parameters, which specify the kernel function, 
the basis function coefficients, here a constant, noise variance, and to form the underlying 
covariance and mean function from which inference about new cases are made73. In this case, the 
kernel is the squared exponential: 𝜎𝜎𝑓𝑓2exp �−|𝐱𝐱−𝐱𝐱´|22𝑙𝑙2 �. Two classes were established: narcolepsy type 1 
and “other”, which contains every other subject. These were labelled 1 and -1 respectively, placing 
all estimates in this range. For more information on GP in general, see the textbook by Rasmussen 
and Williams (2006)73, while more information on variational inference for scalable GP classification 
can be found in the paper by Hensman, Matthews and Ghahramani (2015)74 and Matthews et al. 
(2017)75. 
 
HLA-DQB1*06:02 testing 
HLA testing plays a role in T1N diagnosis, as 97% of patients are DQB1*06:02 positive when the 
disease is defined biochemically by low CSF hypocretin-15 or by the presence of cataplexy and clear 
MSLT findings10. As testing for HLA-DQB1*06:02 only requires a single blood test, models in which 
this feature was included were also tested. The specific feature was implemented as a binary-valued 
predictor, resulting in negative narcolepsy predictions for subjects with a negative HLA test result. 
High pretest probability sample 
MSLT are typically performed in patients with daytime sleepiness that cannot be explained by OSA, 
insufficient/disturbed sleep or circadian disturbances. These patients have a higher pretest 
probability of having T1N than random clinical patients. Patients are then diagnosed with type 1 or 
type 2 narcolepsy, idiopathic hypersomnia or subjective sleepiness based on MSLT results, 
cataplexy symptoms, and HLA results (if available). To test whether our detector differentiates T1N 
from these other cases with unexplained sleepiness, we conducted a post hoc analysis of the 
detector performance in these subjects extracted from both the test and replication datasets. 
Data and code availability 
All the software is made available in GitHub at: [https://github.com/stanford-stages/stanford-
stages].  We asked all contributing co-authors whether we could make the anonymized EDF 
available, together with age, sex and T1N diagnosis (Y/N). The SSC10,32 (Emmanuel  Mignot), the 
IS-RC31 (Sam Kuna, Clete Kushida, Paula K. Schweitzer), the KHC (Seung Chul Hong), the HIS 
(Giuseppe Plazzi), the DHS (Poul Jennum), the FHC (Yves Dauvilliers), and associated data is 
available at [https://stanfordmedicine.app.box.com/s/r9e92ygq0erf7hn5re6j51aaggf50jly]. The AHC 
(Birgit Högl), and the CNC12 (Fang Han) are available from the corresponding investigator on 
reasonable request. The WSC32,33 data analysed during the current study are not publicly available 
due to specific language contained in informed consent documents limiting use of WSC human 
subjects’ data to specified institutionally-approved investigations. However, WSC can be made 
available from Paul Peppard on reasonable request and with relevant institutional review board(s) 
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approval.  The JCTS43 and AASM ISR16 dataset are available from the corresponding institutions 
on reasonable request.  
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FIGURE LEGENDS 
Figure 1 Accuracy per scorer and by time resolution 
a The effect on scoring accuracy as golden standard is improved. Every combination 
of N scorers is evaluated in an unweighted manner and the mean is calculated. 
Accuracy is shown with mean (solid black line) and a 95% confidence interval (grey 
area). 
b  Predictive performance of best model at different resolutions. Performance is 
shown as mean accuracy (solid black line) with a 95% confidence interval (grey 
area). 
  
Figure 2 Hypnodensity example evaluated by multiple scorers and different predictive models 
a The Figure displays the hypnodensity graph. Displayed models are, in order: 
Multiple scorer assessment (1); ensembles as described in Supplementary Table 8: 
All models, those with memory (LSTM) and those without memory (FF) (2-4); single 
models, as described in Supplementary Table 8 (5-7). OCT is octave encoding, 
Color codes: White – wake, red – N1, light blue – N2, dark blue – N3, black – REM.  
b 150 epochs of a recording from the AASM ISR program are analyzed by 16 
models with randomly varying parameters, using the CC/SH/LS/LSTM model as a 
template. This data was also evaluated by 5234±14 different scorers. The 
distribution of these is shown on top, the average model predictions are shown 
middle, and the model variance is shown at the bottom. 
 
Figure 3 
 
Examples of hypnodensity graph in subjects with and without narcolepsy 
Hypnodensity, i.e. probability distribution per stage of sleep for a subject without 
narcolepsy (top) and a subject with narcolepsy (Bottom). Color codes: White – wake, 
red – N1, light blue – N2, dark blue – N3, black – REM 
 
Figure 4 Diagnostic receiver operating characteristics curves 
Diagnostic receiver operating characteristics (ROC) curves, displaying the trade-
offs between sensitivity and specificity in for the our narcolepsy biomarker for a 
training sample, b testing sample, c replication sample, and e high pre-test sample. 
d-f Adding HLA to model vastly increases specificity. Cut-off thresholds are 
presented for models with (red dot) and without HLA (green dot). 
 
Figure 5 Overall Design of the study 
a Pre-processing steps taken to achieve the format of data as it is used in the neural 
networks. One of the 5 channels is first high-pass filtered with a cut-off at 0.2 Hz, 
then low-pass filtered with a cut-off at 49 Hz followed by a re-sampling to 100 Hz to 
ensure data homogeneity. In the case of EEG signals, a channel selection is 
employed to choose the channel with the least noise. The data is then encoded 
using either the CC or the octave encoding. 
b Steps taken to produce and test the automatic scoring algorithm. A part of the 
SSC10,32 and WSC32,33 is randomly selected, as described in Supplementary Table 
1. This data is then segmented in 5 minute segments and scrambled with segments 
from other subjects to increase batch similarity during training. A neural network is 
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then trained until convergence (evaluated using a separate validation sample). Once 
trained, the networks are tested on a separate part of the SSC and WSC along with 
data from the IS-RC31 and KHC10,34. 
c Steps taken to produce and test the narcolepsy detector. Hypnodensities are 
extracted from data, as described in Supplementary Table 1. This data is separated 
into a training (60%) and a testing (40%) split. From the training split, 481 potentially 
relevant features, as described in Supplementary Table 9, are extracted from each 
hypnodensity. The prominent features are maintained using a recursive selection 
algorithm, and from these features a GP classifier is created. From the testing split, 
the same relevant features are extracted, and the GP classifier is evaluated. 
 
Figure 6 
 
Neural network strategy 
a An example of the octave and the CC encoding on 10 seconds of EEG, EOG and 
EMG data. This processed data is fed into the neural networks in one of the two 
formats. The data in the octave encoding is offset for visualization purposes. Colour 
scale is unitless. 
b Simplified network configuration, displaying how data is fed and processed 
through the networks. A more detailed description can be found in Supplementary 
Figure 3. 
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TABLES 
Table 1: Individual and overall scorer performance, expressed as accuracy (upper Table) and Cohen’s kappa (lower 
Table). Both accuracy and Cohen’s kappa are presented as both with (biased) and without (unbiased) the assessed 
scorer included in the consensus standard in a leave-one-out fashion. Accuracy is expressed in percent, and 
Cohen’s kappa is a ratio, and therefore unitless. T-statistics and p-values corresponds to the paired t-test between 
the unbiased predictions for each scorer against the model predictions on the same consensus. 
 Overall Scorer 1 Scorer 2 Scorer 3 Scorer 4 Scorer 5 Scorer 6 
Accuracy (%), 
Biased 81.3±3.0 82.4±6.1 84.6±5.5 74.1±7.9 85.4±5.7 83.1±9.4 78.3±8.9 
Accuracy (%), 
unbiased 76.0±3.2 77.3±6.3 79.1±6.3 69.0±8.0 79.7±6.5 77.8±9.6 72.9±9.2 
Model 
accuracy (%) 
on concensus 
- 85.1±4.9 83.8±5.0 86.5±4.3 84.3±4.7 85.6±4.7 87.0±4.5 
t-stat (p-value) - 9.5 (3.8×10-14) 6.6 (7.5×10-9) 18.3 (6.0×10-28) 6.7 (4.7×10-9) 6.4 (1.7×10-8) 12.2 (7.5×10-19) 
Cohen’s 
kappa, biased 61.0±6.8 63.6±12.2 68.4±10.5 45.6±19.7 69.6±13.2 64.5±20.9 54.5±19.8 
Cohens’ 
kappa, 
unbiased 
57.7±6.1 61.3±11.2 64.6±10.3 43.5±19.2 64.6±13.1 60.9±16.9 51.6±16.7 
Model kappa 
on concensus - 74.3±12.3 72.4±12.1 76.0±11.8 72.7±12.0 74.7±12.1 76.6±12.2 
t-stat (p-value) - 9.5 (4.6×10-14) 7.1 (7.9×10-10) 15.4 (7.0×10-24) 6.6 (6.4×10-9) 7.1 (9.2×10-10) 13.2 (2.0×10-20) 
 
  
 33 
Table 2: Performance of best models, as they are described by Supplementary Table 8, on various data-sets 
compared to the six-scorer consensus. All comparisons are on a by-epoch-basis. 
 
Test Data 
Best 
Single Model Mean Performance (%) 
Best 
Ensemble Mean Performance (%) 
WSC CC/SH/LS/LSTM/2 86.0±5.0 All CC 86.4±5.2 
SSC+KHC 
No narcolepsy CC/LH/SS/LSTM 76.9±11.1 All CC 77.0±11.9 
SSC+KHC Narcolepsy CC/LH/SS/LSTM 68.8±11.0 All CC 68.4±12.2 
IS-RC CC/LH/LS/LSTM/2 84.6±4.6 All Models 86.8±4.3 
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Table 3: Confusion matrix displaying the relation between different targets and the ensemble estimate. The 
targets are: Top row – un-weighted consensus. Bottom row – weighted by the scorer agreement at each 
epoch. The number of analyzed epochs were 53009 (un-weighted) and 36032 (weighted). 
Target 
M
od
el
 p
re
di
ct
io
n 
Stages Wake N1 N2 N3 REM  
Wake 
14.08% 
16.68% 
0.35% 
0.15% 
0.88% 
0.44% 
0.007% 
0.003% 
0.08% 
0.02% 
0.91 
0.96 
N1 
1.13% 
0.47% 
1.78% 
0.88% 
3.00% 
1.15% 
0.002% 
0% 
0.36% 
0.12% 
0.28 
0.34 
N2 
0.29% 
0.12% 
0.59% 
0.25% 
52.58% 
56.30% 
1.27% 
0.34% 
0.66% 
0.32% 
0.95 
0.98 
N3 
0.002% 
0% 
0% 
0% 
2.13% 
1.09% 
4.87% 
4.23% 
0% 
0% 
0.70 
0.91 
REM 
0.54% 
0.40% 
1.17% 
0.73% 
0.78% 
0.41% 
0% 
0% 
13.45% 
15.86% 
0.84 
0.91 
 0.88 
0.94 
0.46 
0.44 
0.89 
0.95 
0.79 
0.92 
0.92 
0.97 
0.87 
0.94 
 
 
  
 35 
Table 4: Descriptions of the 8 most frequently selected features. 
Number Relative 
selection 
frequency 
Description 
1 1 The time taken before 5% of the sum of the product between W, N2 and REM, 
calculated at every epoch, has accumulated, weighed by the total amount of 
this sum.  
This feature expresses the known sleep stage dissociation and altered sleep 
timing. 
2 0.91 The number of nightly SOREMPS appearing throughout the recording. 
3 0.82 The time taken before 50% of the wakefulness in a recording has 
accumulated, weighed by the total amount of wakefulness. 
4 0.82 REM 6 
The Shannon entropy of the REM sleep stage distribution. This expresses the 
amount of information held in a signal, or in this case, how many different 
values the REM sleep stage distribution obtains – how consolidated phases of 
REM are when the stage appears. 
5 0.68 The maximum probability of wakefulness obtained in a recording.  
6 0.68 The maximum value obtained of the product between the N2 and REM 
probability in a recording. 
7 0.68 The time taken before 30% of the sum of the product between W and N2, 
calculated at every epoch, has accumulated, weighed by the total amount of 
this sum.  
8 0.64 The time taken before 10% of the sum of the product between W and N1, 
calculated at every epoch, has accumulated, weighed by the total amount of 
this sum. 
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